The first results from the MesomiR 1 trial, a phase I clinical trial of a targeted delivery of a microRNA-based therapy, were published yesterday in the American Journal of Respiratory and Critical Care Medicine
The trial is a collaboration between ADRI, the Sydney-based biotech company EnGeneIC Ltd and three hospitals in Sydney. The treatment consists of EnGeneIC’s EDV(TM)nanocell delivery system, loaded with microRNA mimics developed by ADRI scientists, designed to restore levels of a family of microRNAs that are present at reduced levels in mesothelioma and lung cancer patients. The trial was made possible by a generous bequest by the Andrew Lloyd family, grants from the Cancer Institute NSW and Work Cover, and additional financial support from the John T Reid Charitable Trust and James Hardie Industries.
The paper describes the results the first cohort of 6 patients, all with mesothelioma, and includes details of the near-complete response in one patient. The trial – designed to investigate safety and optimal dose – is ongoing, with additional trials planned for the future.
For more information, please contact email@example.com